



Identifiers & Pagination:

Year: 2026

Volume: 17

Publisher ID: 22205187.17.89

Correspondence:

Taha Nazir
PhD, Researcher, Worker, and
Journalist. Thomson Reuters - ID
N-5730-2015 | ORCID ID -
orcid.org/0000-0002-5308-
6798 | <https://tahanazir.com>

Citation:

Taha Nazir (2026). Molecular
determinants and genomic
tracking of bacterial
antimicrobial resistance:
Advancing precision medicine
and epidemiological control.
Pharm Rev. Vol. 17.2026. P. 89-
93.

<http://dx.doi.org/10.5281/zenodo.15644149>

Conflict of interest:

Author accepts all potential
conflict of interest.

Funding:

The authors received no direct
funding.

Ethics approval:

No ethical approval needed for
this work.

Consent for publication:

Author is agreed to publish this
article.

Editorial Article

MOLECULAR DETERMINANTS AND GENOMIC TRACKING OF BACTERIAL ANTIMICROBIAL RESISTANCE: ADVANCING PRECISION MEDICINE AND EPIDEMIOLOGICAL CONTROL

Taha Nazir

1. Editor-in-Chief, Pharmaceutical Review. ISSN 2220-5187
| <http://pharmaceuticalsreview.ca> | <https://pharmaceuticalsreview.com>
2. Ex-President - Pharmacist Federation (Pakistan).
<http://pharmacistfed.wordpress.com>

[ORCID](#) | [Publons](#) | [ResearchGate](#) | [Scopus](#) | [Academia](#) |
[Linkedin](#) | [Google Scholar](#) | [Loop Frontiers](#) | [Twitter](#) |
[Instagram](#) | [Scinapse](#)

Running title:antimicrobial resistance, bacterial genomics,
molecular determinants

Keywords:resistance genes, precision medicine, epidemiology,
genomic surveillance, antibiotic stewardship

Data Source: biotechnology, environmental microbiology,
microbial ecology, ecosystem sustainability, public health

Abstract:

The emergence and spread of bacterial antimicrobial resistance (AMR) pose a critical threat to public health and clinical outcomes worldwide. This paper explores molecular determinants and genomic approaches for tracking AMR, including resistance genes, plasmids, mutations, and mobile genetic elements. By integrating whole-genome sequencing, PCR-based detection, and bioinformatic analyses, researchers can precisely identify resistance mechanisms, monitor epidemiological patterns, and guide targeted therapeutic interventions. Advancing molecular and genomic surveillance enhances precision medicine, informs antibiotic stewardship, and strengthens public health strategies to mitigate the global burden of resistant infections.

Antimicrobial Resistance

Antimicrobial resistance (AMR) epitomizes the molecular triumph of bacterial adaptability under the selective pressure of antibiotic exposure. Driven by spontaneous mutations, horizontal gene transfer (HGT), and the mobilization of resistance determinants via plasmids, transposons, and integrons, bacteria continuously evolve to neutralize the effects of therapeutic agents. This genetic plasticity enables the survival of resistant clones across diverse ecological niches, from hospital intensive care units to wastewater systems.

Clinically significant resistance genes—*bla*NDM, *bla*KPC, *bla*OXA-48 (carbapenemases), *mecA* (methicillin resistance in *Staphylococcus aureus*), *vanA* (vancomycin resistance in *Enterococcus faecium*), and *mcr-1* (colistin resistance in *E. coli*)—demonstrate how molecular innovation translates into therapeutic failure. The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, including MRSA, VRE, ESBL-producing *Enterobacteriaceae*, and carbapenem-resistant *Acinetobacter baumannii*, underscores how microbial evolution now outpaces antibiotic discovery.

Molecular Mechanisms

Bacteria employ multifaceted defense systems that interact at genetic, biochemical, and structural levels to resist antimicrobial agents.

Enzymatic Degradation and Chemical Modification of Antibiotics:

The production of β -lactamases remains the most widespread mechanism, hydrolyzing the β -lactam ring of penicillins and cephalosporins. Extended-spectrum β -lactamases (ESBLs), metallo- β -lactamases (e.g., NDM-1, VIM, IMP), and serine carbapenemases (KPC, OXA-type) confer resistance even to carbapenems—often considered last-resort antibiotics.

Aminoglycoside-modifying enzymes (acetyltransferases, phosphotransferases, nucleotidyltransferases) chemically inactivate drugs, reducing their affinity for bacterial ribosomes.

Modification of Antimicrobial Targets:

Mutations in *gyrA* and *parC* genes alter DNA gyrase and topoisomerase IV, producing high-level fluoroquinolone resistance. Methylation of 23S rRNA via *erm* genes renders ribosomes insensitive to macrolides, while *vanA* and *vanB* modify peptidoglycan precursors, transforming vancomycin binding sites and conferring glycopeptide resistance.

Efflux-Mediated Drug Expulsion and Reduced Membrane Permeability:

Efflux pump systems such as AcrAB-TolC (*E. coli*), MexAB-OprM (*Pseudomonas aeruginosa*), and NorA (*S. aureus*) actively expel diverse antibiotics, maintaining intracellular concentrations below lethal thresholds. Simultaneously, loss or alteration of porins (e.g., OmpF, OprD) in Gram-negative bacteria restricts antibiotic entry, particularly affecting β -lactams and quinolones.

Biofilm Development and Persistence Phenotypes as Evolutionary Shields:

Bacteria forming biofilms—such as *Pseudomonas aeruginosa* in cystic fibrosis lungs or *Staphylococcus epidermidis* on catheters—exhibit up to 1,000-fold greater resistance due to extracellular polymeric barriers, metabolic dormancy, and quorum-sensing coordination. Biofilm-associated cells, or “persisters,” remain phenotypically tolerant, evading both immune clearance and antibiotic therapy.

Horizontal Gene Transfer

Horizontal gene transfer (HGT) functions as the genetic engine of AMR evolution, allowing bacteria to acquire resistance determinants from phylogenetically unrelated species.

Conjugation involves plasmid-mediated transfer through pilus-dependent contact. R-plasmids frequently carry multidrug-resistance genes, including *bla*TEM, *bla*CTX-M, and *mcr*-I, facilitating interspecies dissemination among Enterobacteriaceae.

Transformation allows naturally competent bacteria—such as *Neisseria gonorrhoeae*, *Streptococcus pneumoniae*, and *Acinetobacter baylyi*—to integrate free DNA fragments from their surroundings, incorporating resistance determinants into their chromosomes.

Transduction occurs when bacteriophages package and transfer resistance genes, contributing to the mosaic genome structures observed in pathogenic bacteria. Integrons, particularly class 1 integrons, act as adaptive gene-capturing systems, assembling multiple resistance cassettes and ensuring their co-expression under antibiotic pressure.

Advanced Genomic Surveillance

Modern genomic technologies have redefined bacteriological surveillance by enabling comprehensive genetic characterization of pathogens at the population level. Whole Genome Sequencing (WGS) allows complete mapping of chromosomal and plasmid-encoded resistance genes, revealing microevolutionary changes driving outbreaks. For example, WGS has traced the global expansion of *Klebsiella pneumoniae* ST258 carrying *bla*KPC and *E. coli* ST131 harboring *bla*CTX-M-15.

Comparative genomics identifies conserved and variable regions among strains, distinguishing clonal dissemination from independent emergence events. Pan-genomic analysis differentiates core genes (shared by all isolates) from accessory genes (often conferring virulence or resistance). Metagenomic sequencing further extends this surveillance to environmental reservoirs—detecting resistance genes in soil, water, and animal microbiomes, reinforcing the *One Health* perspective of AMR.

Single Nucleotide Polymorphism (SNP) analysis provides fine-scale phylogenetic resolution for outbreak tracking, while plasmidome profiling deciphers mobile genetic architectures promoting interspecies resistance transfer. Bioinformatics databases such as CARD (Comprehensive Antibiotic Resistance Database), ResFinder, and NCBI Pathogen Detection integrate genomic data to predict resistance phenotypes, enabling early intervention and public health response.

Molecular Typing and Digital Epidemiology

Epidemiological tracing of resistant bacterial strains now depends on high-resolution molecular typing systems. Traditional methods such as Pulsed-Field Gel Electrophoresis (PFGE) and Multilocus Sequence Typing (MLST) remain valuable, while more advanced genomic tools like Core Genome MLST (cgMLST) and SNP-based typing offer unprecedented precision. Repetitive sequence-based PCR (rep-PCR), Amplified Fragment Length Polymorphism (AFLP), and Random Amplified Polymorphic DNA (RAPD) analyses distinguish closely related clones, supporting hospital outbreak investigations. Integration of artificial intelligence (AI) and machine learning into genomic surveillance pipelines enhances predictive modeling—identifying emerging resistance hotspots, forecasting gene dissemination routes, and guiding antimicrobial stewardship protocols with algorithmic precision.

Future of Bacteriological Surveillance

Next-generation bacteriology is rapidly transitioning from reactive detection to proactive prediction. CRISPR-based diagnostic platforms such as SHERLOCK and DETECTR now allow rapid, point-of-care identification of resistance genes with single-molecule sensitivity. Nanopore sequencing provides real-time, portable genome analysis, enabling field-based outbreak tracking and hospital-level infection surveillance.

Artificial intelligence-driven genomic analytics transform raw sequencing data into actionable clinical insights—predicting antimicrobial susceptibility patterns, identifying novel resistance genes, and optimizing empirical therapy selection. The convergence of genomics, molecular epidemiology, and digital informatics defines a new paradigm of *precision bacteriology*—a discipline capable of predicting evolutionary trajectories, informing global antimicrobial policy, and sustaining the future efficacy of antibiotics.

Conclusion

The escalating crisis of bacterial resistance demands a paradigm shift from conventional microbiological diagnostics toward integrative molecular and computational surveillance systems. By combining genomic sequencing, bioinformatics, and evolutionary analytics, modern bacteriology now functions as both a diagnostic science and a predictive discipline. The fusion of clinical microbiology with global genomic intelligence ensures that bacterial evolution is not merely observed—but anticipated, contained, and ultimately controlled through data-driven precision medicine and collective international vigilance.

Editorial Statement:

This is research-based manuscript, prepared and structured in a scientific manner. Modern AI-assisted tools used to access current and authentic info. The digital archives, bibliographic databanks, online libraries, research articles, academic repositories and encyclopedias employed.

Preprint Notice:

This manuscript is shared as a non–peer-reviewed preprint on platforms such as Zenodo, SSRN, and Research Square to support scholarly discussion. The content is research-based and developed using publicly available and verifiable sources. Readers are encouraged to interpret the material as preliminary and subject to revision.

Disclaimer:

This non–peer-reviewed article is shared for general academic discussion. AI tools were used to assist with clarity and organization. Readers are advised to independently assess and verify the information.

References:

- [1] Munita JM, Arias CA. Mechanisms of antibiotic resistance. *Microbiol Spectr*. 2016;4(2):10.1128. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888806/>
- [2] World Health Organization. **Global action plan on antimicrobial resistance** [Internet]. WHO; 2024. Available from: <https://www.who.int/activities/global-action-plan-on-antimicrobial-resistance>
- [3] Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev*. 2010;74(3):417–433. Available from: <https://journals.asm.org/doi/10.1128/MMBR.00016-10>

- [4] Laxminarayan R, et al. Antibiotic resistance—the need for global solutions. *Lancet Infect Dis*. 2013;13(12):1057–1098. Available from: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(13\)70318-9/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(13)70318-9/fulltext)
- [5] Didelot X, Bowden R, Wilson DJ, Peto TE, Crook DW. Transforming clinical microbiology with bacterial genome sequencing. *Nat Rev Genet*. 2012;13:601–612. Available from: <https://www.nature.com/articles/nrg3226>
- [6] van Belkum A, et al. Developmental roadmap for antimicrobial susceptibility testing systems. *Nat Rev Microbiol*. 2019;17:51–62. Available from: <https://www.nature.com/articles/s41579-018-0113-7>
- [7] Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev*. 2008;21(3):538–582. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2519807/>
- [8] National Institutes of Health. **Genomic approaches to study antimicrobial resistance** [Internet]. NIH; 2025. Available from: <https://www.nih.gov>
- [9] Centers for Disease Control and Prevention. **Antibiotic resistance threats in the United States, 2019** [Internet]. CDC; 2019. Available from: <https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf>
- [10] Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). *Proc Natl Acad Sci USA*. 2002;99(11):7687–7692. Available from: <https://www.pnas.org/doi/10.1073/pnas.122108599>



©2026 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution

— You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions: You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.